Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue SUPPL. 1, 2004, Pages 40-48

  Edwards, Keith R ^a,b   Hershey, Linda ^c   Wray, Laura ^c   Bednarczyk, Edward M ^d   Lichter, David ^c   Farlow, Martin ^e   Johnson, Stewart ^f  

^a Neurological Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e INDIANA UNIVERSITY   (United States)

^f WILLIAMS COLLEGE   (United States)

Author keywords

Cholinesterase inhibitors; Dementia with Lewy bodies (DLB); Galantamine; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

ADULT; AGED; ANOREXIA; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DELUSION; DEMENTIA; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HALLUCINATION; HEART INFARCTION; HUMAN; LEWY BODY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; PARKINSONISM; POLYDIPSIA; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SLEEP PATTERN; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREMOR; VERTIGO; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; LEWY BODY DISEASE; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; TREATMENT OUTCOME; URIDINE;

EID: 0346749726     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074681     Document Type: Article

References (51)

1. Forstl H, Levy R: FH Lewy on Lewy bodies, parkinsonism and dementia. Int J Geriatr Psychiatry 1991;6:757-766.
2. Woodard JS: Concentric hyaline inclusion body formation in mental disease: Analysis of twenty-seven cases. J Neuropathol Exp Neurol 1962;2:442-449.
3. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK: Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
4. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M: The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990;40:1-8.
5. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R: Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74:720-724.
6. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
7. McKeith IG, Perry EK, Perry RH: Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Neurology 1999;53:902-905.
8. Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, Hyman BT: Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009.
9. Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999;53:1974-1982.
10. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
11. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
12. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O'Brien J, Holmes C, Perry E: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-876.
13. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E: Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999;73:1590-1597.
14. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
15. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-638.
16. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
17. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
18. Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998;11:211-216.
19. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
20. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R: Effects of rivastigmine on cognitive function in dementia with lewy bodies: A randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-192.
21. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
22. Maelicke A, Albuquerque EX: Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000;393:165-170.
23. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A: Modulation of nicotinic receptor activity in the central nervous system: A novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15(suppl 1):S19-S25.
24. Maelicke A: Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(suppl 1):11-18.
25. Zhou FM, Liang Y, Dani JA: Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001;4:1224-1229.
26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
27. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
28. Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Dementia with Lewy bodies: Findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034-1045.
29. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK: The cognitive drug research computerized assessment system for demented patients: A validation study. Int J Geriatr Psychiatry 1991;6:95-102.
30. Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, Pitt BM: The cognitive drug research computerized assessment system in the evaluation of early dementia - is speed of the essence? Int J Geriatr Psychiatry 1995;10:199-206.
31. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32.
32. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
33. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
34. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
35. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG: The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256.
36. Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson's disease rating scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. Florham Park, NJ, MacMillan Healthcare Information, 1987, pp 153-304.
37. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, Campbell M, Perry R, Ince P: The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997;96:366-371.
38. Ballard C: Psychiatric features and longitudinal course. Platform presentation at the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia (DLB/PDD), Newcastle-upon-Tyne, UK, September 17-20, 2003.
39. Perry E: Neurochemical pathology of DLB. Platform presentation at the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia (DLB/PDD), Newcastle-upon-Tyne, UK, September 17-20, 2003.
40. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
41. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
42. Wei Z, Qing H, Shao Z, Mousseau D, Dyck L, Li X: Atypical antipsychotics attenuate the neurotoxicity of MPP and Beta-amyloid in PC12 cells. Poster presented at the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia (DLB/PDD), Newcastle-upon-Tyne, UK, September 17-20, 2003.
43. Lopez M: Neuroprotection by galantamine in cultured cells. Platform presentation at the AD/PD Annual Meeting, Seville, Spain, May 2003.
44. Lahiri D: Neuroprotection by galantamine by reduction of toxicity. Platform presentation at the AD/PD Annual Meeting, Seville, Spain, May 2003.
45. Olson EJ, Boeve BF, Silber MH: Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
46. Boeve B: Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-45.
47. Blesa R: Galantamine: Therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(suppl 1):28-34.
48. Wesnes KA, Scott M, Morrison S, Greenwood D, Russell-Duff K, Wilcock GK: The effects of galantamine on attention in Alzheimer's disease. J Psychopharmacol 1998;12(suppl A):A64.
49. Ballard C, O'Brien J, Gray A, Cormack F, Ayre G, Rowan E, Thompson P, Bucks R, McKeith I, Walker M, Tovee M: Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001;58:977-982.
50. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA: Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992;108:485-494.
51. Ueno K, Togashi H, Matsumoto M, Ohashi S, Saito H, Yoshioka M: a4b2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder. J Pharmacol Exp Ther 2002;302:95-100.